These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 30677465

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P, HARBOR Study Group.
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
    Adrean SD, Chaili S, Ramkumar H, Pirouz A, Grant S.
    Ophthalmology; 2018 Jul; 125(7):1047-1053. PubMed ID: 29439828
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
    Inan S, Baysal Z, Inan UU.
    Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
    [Abstract] [Full Text] [Related]

  • 29. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Stoller GL, Kokame GT, Dreyer RF, Shapiro H, Tuomi LL.
    JAMA Ophthalmol; 2016 May 12; 134(5):545-553. PubMed ID: 27010625
    [Abstract] [Full Text] [Related]

  • 30. Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Gune S, Abdelfattah NS, Karamat A, Balasubramanian S, Marion KM, Morgenthien E, Sadda SR.
    Ophthalmology; 2020 Apr 12; 127(4):523-532. PubMed ID: 31718842
    [Abstract] [Full Text] [Related]

  • 31. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
    Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, Balaskas K, Burton BJL, Downes SM, Eleftheriadis H, George S, Gilmour D, Hamilton R, Lotery AJ, Patel N, Prakash P, Santiago C, Thomas S, Varma D, Walters G, Williams M, Wolf A, Zakri RH, Igwe F, Ayan F.
    Br J Ophthalmol; 2020 Apr 12; 104(4):493-499. PubMed ID: 31383649
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.
    Monés J, Biarnés M, Trindade F, Casaroli-Marano R.
    Graefes Arch Clin Exp Ophthalmol; 2012 Dec 12; 250(12):1737-44. PubMed ID: 22527314
    [Abstract] [Full Text] [Related]

  • 34. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ, Comparison of Age-related Macular Degeneration Treatments Trials Research Group.
    Ophthalmology; 2016 Apr 12; 123(4):865-75. PubMed ID: 26783095
    [Abstract] [Full Text] [Related]

  • 35. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL, Fraser-Bell S, Cozzi M, Staurenghi G, Invernizzi A, Monteduro D, Munk MR, Hong T, Chang AA.
    Ophthalmology; 2020 Dec 12; 127(12):1663-1673. PubMed ID: 32544561
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ.
    Retina; 2019 Apr 12; 39(4):664-669. PubMed ID: 29324593
    [Abstract] [Full Text] [Related]

  • 38. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D, London NJ, Khurana RN, Dugel PU, Gune S, Hill L, Tuomi L.
    Ophthalmology; 2016 Oct 12; 123(10):2213-24. PubMed ID: 27566855
    [Abstract] [Full Text] [Related]

  • 39. EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.
    Rahimy E, Ying GS, Pan W, Hsu J.
    Retina; 2019 Apr 12; 39(4):636-647. PubMed ID: 29517580
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.